Follistatin-344 Peptide Research: Myostatin Neutralization, SMAD2/3 Pathway Inhibition, and Preclinical Muscle Growth Evidence

Follistatin-344 is not a peptide and not a compound that has been studied by direct systemic administration; FST344 is the name of an alternatively spliced transcript of the human FST gene whose 344-residue precursor is processed to the 315-residue circulating protein FS315, and essentially the entire preclinical and clinical literature on it uses adeno-associated viral gene delivery rather than injection of the protein. Follistatin-344 research matters because follistatin is one of the most effective known antagonists of myostatin (GDF-8) and activin A, two TGF-beta superfamily ligands that suppress skeletal muscle growth through SMAD2/3, and because the FST344 isoform, unlike FST288, circulates rather than sticking to cell-surface proteoglycans. This article summarises what the primary papers report and corrects several claims that circulated in the earlier version of this page. Follistatin is not a compound in the Maple Research Labs catalogue.

Disclaimer: For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use. The information presented here is drawn from published scientific literature and is intended solely for educational reference.

Isoforms: What FST344, FS315 and FS288 Actually Are

The human FST gene produces two primary transcripts by alternative splicing. The longer one encodes a 344-residue precursor; after signal peptide cleavage the mature protein is 315 residues and is designated FS315. The shorter transcript yields the 288-residue FS288, which lacks the acidic 26-residue C-terminal tail. A third form, FS303, is found in follicular fluid and is thought to arise by proteolytic trimming of that tail. Their activin-binding affinities are comparable, but their cell-surface binding differs markedly in the order FS288 greater than FS303 greater than FS315, because the C-terminal tail interferes with binding to cell-surface heparan sulfate proteoglycans (Sidis et al., 2006, Endocrinology 147:3586-3597; PMID 16627583). A FS315-specific immunoassay confirmed that FS315 is the major circulating isoform and is undetectable in follicular fluid, so the isoforms are genuinely compartmentalised (Schneyer et al., 2004, J Clin Endocrinol Metab 89:5067-5075; PMID 15472207).

That difference has a functional consequence that is often reported backwards. Because inhibition of endogenous activin correlates with surface binding rather than with binding affinity, FS288 suppressed activin-dependent TT cell proliferation while FS315 enhanced it in the same assay, and anchoring the non-binding relative FSTL3 to the membrane dramatically increased its inhibitory activity (Sidis 2006). FS315 is therefore the systemically distributed but locally weaker isoform. The clinical programmes chose FS344 precisely for that reason: the review by Al-Zaidy and colleagues states that FS344 was selected over FS288 because its lower activin affinity limits interference with the pituitary activin-inhibin axis and with follicle-stimulating hormone secretion (Al-Zaidy et al., 2015, J Neuromuscul Dis 2:185-192; PMID 27858738).

Target Pathway: Myostatin, Activin and the Type II Receptors

Myostatin is the TGF-beta family member whose loss produces the double-muscled phenotype in Belgian Blue and Piedmontese cattle, through an 11-nucleotide frameshift deletion and a cysteine-to-tyrosine missense mutation respectively, mirroring the myostatin-null mouse (McPherron and Lee, 1997, PNAS 94:12457-12461; PMID 9356471). Lee and McPherron then worked out how to block it. Purified myostatin is a non-covalent complex of the N-terminal propeptide with a disulfide-linked C-terminal dimer; the C-terminal dimer binds ActRIIB and, less well, ActRIIA; and that binding is inhibited by follistatin and, at higher concentrations, by the propeptide. Transgenic mice expressing the propeptide, follistatin, or a dominant-negative ActRIIB under a skeletal-muscle promoter all showed dramatic increases in muscle mass comparable to myostatin knockouts (Lee and McPherron, 2001, PNAS 98:9306-9311; PMID 11459935). The “approximately 200 percent increase versus roughly 100 percent in myostatin nulls” comparison previously on this page is not what the paper says: the transgenic increases were comparable to, not double, the knockout.

The structural basis came later. The crystal structure of myostatin bound to FS288 shows that the prehelix region of myostatin closely resembles that of the TGF-beta class and that swapping this region into activin A confers signalling through the non-canonical type I receptor Alk5; that the N-terminal domain of FS288 rearranges conformationally to bind myostatin and probably confers specificity; and that the complex creates a continuous electropositive surface which raises heparin affinity, strengthening cell-surface interaction and enhancing myostatin degradation in the presence of either FS288 or FS315 (Cash et al., 2009, EMBO J 28:2662-2676; PMID 19644449). The earlier version of this page attributed a 2.7 angstrom structure to “Harber et al. 2006” and described a 2:1 follistatin-to-dimer stoichiometry with a low-picomolar Kd; the real structural paper is Cash 2009 and it reports neither of those numbers.

Downstream, follistatin-induced hypertrophy is not simply de-repression. Kalista and colleagues showed that a dominant-negative IGF-I receptor in skeletal muscle blunted follistatin-induced fibre hypertrophy by 63 percent, that a dominant-negative Akt reduced it by 65 percent, that rapamycin reduced it by 36 percent, and that IGF-II knockout mice hypertrophied normally, placing the IGF-IR / Akt / mTOR axis as a mandatory mediator of the effect (Kalista et al., 2012, Endocrinology 153:241-253; PMID 22087027).

Preclinical Gene Delivery: Primates

The study usually cited as “Haidet 2008” is Kota and colleagues in Science Translational Medicine, with Haidet as a co-author. An alternatively spliced human follistatin chosen for its muscle-restricted effect was expressed from an AAV serotype 1 vector, AAV1-FS344, and injected into the quadriceps of cynomolgus macaques, producing pronounced and durable increases in muscle size and strength, with long-term transgene expression causing no abnormal changes in the morphology or function of key organs (Kota et al., 2009, Sci Transl Med 1:6ra15; PMID 20368179). The species is the cynomolgus macaque, not the aged rhesus macaque, and the paper reports no 15.5 percent cross-sectional area figure, no grip-strength p value of 0.003, and no 15-month endpoint of the kind quoted in the earlier version of this page.

Clinical Gene Transfer: Becker Muscular Dystrophy and Inclusion Body Myositis

The first clinical use of FS344 was in Becker muscular dystrophy, where intramuscular AAV1 delivery of the follistatin gene improved ambulation; the trial and its rationale are reviewed by Al-Zaidy and colleagues (2015, J Neuromuscul Dis 2:185-192; PMID 27858738). The better-reported functional dataset is in sporadic inclusion body myositis, where rAAV1.CMV.huFS344 at 6 x 10^11 vg/kg was delivered to the quadriceps of both legs in six subjects alongside an exercise regimen. Six-minute walk distance, annualised to a median one-year change, improved by 56.0 metres per year in treated subjects versus a decline of 25.8 metres per year in eight matched untreated subjects (p = 0.01); four of six treated subjects improved by 58 to 153 metres and two by 5 to 23 metres, with decreased fibrosis and improved regeneration on biopsy (Mendell et al., 2017, Mol Ther 25:870-879; PMID 28279643). The “31.4 metres versus 2.0 metres at week 24” figure attributed to a 2015 Becker trial in the earlier version of this page does not appear in the indexed abstracts and has been replaced with the figures above.

Activin A and Human Cancer Cachexia

The clinical case for targeting activin as well as myostatin comes from the ACTICA study. In 152 patients with colorectal or lung cancer, cachexia was associated with reduced lean and fat mass, reduced physical function, lower quality of life and more anorexia, and plasma activin A was 40 percent higher in cachectic than in non-cachectic patients (p less than 0.001), correlating with the severity measures (Loumaye et al., 2015, J Clin Endocrinol Metab 100:2030-2038; PMID 25751105). That study is from 2015, enrolled 152 patients rather than 84 cachectic plus 60 controls, and reports elevated activin A rather than a lowered follistatin-to-myostatin ratio. The unverifiable “Zhou 2010 LLC model”, “Benny Klimek 2010 C26 22 percent”, “Brown 2011 type IIb +47 percent” and “Dankbar 2015 31 percent trabecular erosion” citations from the earlier version of this page have been removed; Dankbar and colleagues did publish on activin A and osteoclasts in inflammatory arthritis, but the specific figure could not be verified.

Key Research Findings

FST344 is a transcript, not a peptide: its mature product is the 315-residue circulating FS315, which binds activin with affinity comparable to FS288 but binds cell surfaces far more weakly, so it distributes systemically while being the weaker local inhibitor (Sidis 2006; Schneyer 2004). Myostatin loss produces double muscling in cattle and mice (McPherron 1997), myostatin signals through ActRIIB, and follistatin blocks that binding; muscle-specific transgenic expression of follistatin, the myostatin propeptide or dominant-negative ActRIIB each produce muscle mass increases comparable to myostatin knockout (Lee and McPherron 2001). The myostatin-FS288 structure explains the specificity and shows that complex formation raises heparin affinity and accelerates myostatin degradation (Cash 2009). Follistatin-induced hypertrophy requires IGF-IR, Akt and mTOR signalling (Kalista 2012). AAV1-FS344 injected into macaque quadriceps produced durable increases in muscle size and strength with no organ abnormality (Kota 2009). In sporadic inclusion body myositis, AAV1-delivered FS344 improved annualised six-minute walk distance by 56 metres per year against a 25.8 metre per year decline in matched untreated subjects (Mendell 2017), and the same isoform improved ambulation in Becker muscular dystrophy (Al-Zaidy 2015). Plasma activin A is elevated in human cancer cachexia (Loumaye 2015).

Why the Delivery Route Matters for Research Design

Every efficacy result above was obtained either by transgenic expression or by AAV-mediated gene delivery, not by injecting follistatin protein. That is not an accident of fashion. Follistatin is a roughly 35 kDa glycoprotein whose activity depends on correct disulfide-bonded folding of three follistatin domains, and its systemic pharmacokinetics are unfavourable, which is why sustained expression rather than bolus protein has been the approach in every model from mouse to human. Any preparation sold as a lyophilised “follistatin-344 peptide” is a recombinant protein, not a synthetic peptide, and the analytical questions are different in kind: reversed-phase HPLC purity and an intact-mass measurement say nothing about whether the three domains are correctly folded, whether the disulfides have scrambled, or whether the protein retains activin-binding activity. A misfolded or truncated species can look clean by HPLC and be functionally inert.

For a protein of this class the meaningful specifications are identity by peptide mapping or intact mass with a glycosylation statement, aggregate content by size-exclusion chromatography, an endotoxin result for any cell-based or in vivo use, and ideally a functional binding or reporter assay, none of which appear on a standard synthetic-peptide certificate of analysis. Our articles on mass spectrometry identity confirmation, endotoxin testing and reading a certificate of analysis cover what each test does and does not establish. Storage considerations also differ: proteins of this size are more sensitive to freeze-thaw aggregation and to surface adsorption than small synthetic peptides.

Selectivity Considerations

Follistatin neutralises more than myostatin. In competitive binding, myostatin was more potent than BMP-6 and BMP-7, while BMP-2 and BMP-4 were inactive (Sidis 2006), so the selectivity window over the BMPs is real but not absolute, and activin A and activin B are bound with high affinity by design. Because activin signalling controls FSH secretion, systemic follistatin has an endocrine dimension that intramuscular gene delivery of FS344 was specifically chosen to minimise (Al-Zaidy 2015). Any study design using systemic follistatin needs to account for the activin-inhibin axis rather than treating the protein as a myostatin-selective tool.

Note on sources. This article was rewritten in September 2026 after a citation audit. The earlier version described FST344 as a peptide available for systemic administration and stated that Maple Research Labs supplies it with per-batch COAs; follistatin is not in the catalogue and that sentence has been removed. It also cited a “Harber et al. 2006” crystal structure, a “Rodino-Klapac 2009” golden retriever study with a 33 percent fibre diameter and 16-fold necrosis figure, a “Brown 2011” fibre-type study, a “Zhou 2010” LLC study, a “Benny Klimek 2010” C26 study and a “Dankbar 2015” bone figure that could not be located or verified; misattributed the primate study to Haidet in aged rhesus macaques with invented endpoints when it is Kota 2009 in cynomolgus macaques; misreported the Becker trial numbers; misstated the Lee and McPherron 2001 result; gave a low-picomolar Kd, a 2:1 stoichiometry, a 2 to 4 hour half-life and a 0.1 to 10 mg/kg dose range with no source. Every citation above was checked against the indexed abstract on 18 September 2026.

Researchers working on tissue repair in parallel compartments may want the BPC-157 and TB-500 summaries, and the BPC-157 vs TB-500 comparison, all of which act through mechanisms unrelated to the SMAD2/3 axis described here. Maple Research Labs submits manufactured batches of its catalogue compounds to an independent analytical laboratory for HPLC testing and publishes the per-batch result on the certificates of analysis page; the current catalogue is at research peptides and the specification standards are set out in the documentation section.

For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use. All content describes findings from published preclinical and early-phase clinical research.